Kiniksa CFO exercises RSUs, 1,303 shares withheld
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026.
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Each RSU converts into one share and is part of a grant that vests in four equal annual installments starting April 7, 2022.
To cover tax obligations from this vesting, 1,303 Class A Ordinary Shares were withheld at a price of $48.94 per share, rather than sold in the open market. After these compensation-related transactions, Ragosa directly holds 16,154 Class A Ordinary Shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 2,694 | $0.00 | $0.00 |
| Exercise | Class A Ordinary Share | 2,694 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Class A Ordinary Share | 1,303 | $48.94 | $64K |
Footnotes (2)
- F1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
Key Figures
Key Terms
tax-withholding disposition financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kiniksa (KNSA) CFO Mark Ragosa report in this Form 4?
How many Kiniksa (KNSA) RSUs vested and were exercised by the CFO?
What is the vesting schedule for the Kiniksa (KNSA) RSUs granted to the CFO?
AI-generated analysis. How Rhea-AI works. Not financial advice.